Vu Truong, CEO, Aridis Pharmaceuticals is taking on the challenge of making an inhaled monoclonal antibody to treat COVID-19 to allow for the easier patient access.  Drawing on their work in infectious diseases and with a number of monoclonal antibodies candidates to treat bacteria infection associated with superbugs and antibiotic resistance, Aridis is  finding ways to overcome lack of usage of similar potent antibodies from Regeneron and Eli Lilly to combat the coronavirus.